Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Durvalumab + Trabectedin |
Indication/Tumor Type | ovarian carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | ovarian carcinoma | predicted - sensitive | Durvalumab + Trabectedin | Case Reports/Case Series | Actionable | In a Phase Ib trial (TRAMUNE), Yondelis (trabectedin) plus Imfinzi (durvalumab) demonstrated safety and resulted in an objective response rate of 21.4% (3/14, all partial responses), 3- and 6-month progression-free rates of 42.9% and 42.9%, a 1-year progression-free survival (PFS) rate of 7.1%, and a 1-year overall survival rate of 57.1% in patients with ovarian carcinoma, with an improved PFS for patients with CD274 (PD-L1) expression (6.8 mo vs 1.3 mo) (PMID: 34965951; NCT03085225). | 34965951 |
PubMed Id | Reference Title | Details |
---|---|---|
(34965951) | Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study. | Full reference... |